Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

AviadoBio specializes in developing gene therapies for neurodegenerative diseases, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

AviadoBio

Capsida Biotherapeutics is a fully integrated next-generation gene therapy platform company that originated from groundbreaking research at Caltech. The company focuses on capsid engineering, cargo optimization, translational biology, process development and manufacturing, and clinical development, with the goal of creating customized therapies for both rare and common diseases across all ages.

Capsida Biotherapeutics

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Glenmark Pharmaceuticals Limited

Alkermes is a biopharmaceutical company focused on developing medicines for complex neurological and psychiatric disorders. The company employs its neuroscience expertise to create innovative treatment options.

Metric
Company Name	Alkermes plc	AviadoBio	Capsida Biotherapeutics	Glenmark Pharmaceuticals Limited
Symbol	ALKS			GLENMARK
MSH ID	COM:ALKERMES	COM:AVIADOBIO	COM:CAPSIDA	COM:GLENMARKPHARMA
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Drug Manufacturers - Specialty & Generic
Country	IE	GB		IN
Stage
Employee Count	2.10K		51	15.56K
Website	alkermes.com	aviadobio.com	capsida.com	glenmarkpharma.com
LinkedIn
Founders

Metric
Market Cap	3.89B		4.61B
Enterprise Value
Monthly Web Traffic		4.49K
Web Traffic Growth		0.18
Valuation
Raised Capital

Metric
Revenue	1.66B	1.39B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.37B	466.30M
EBITDA	486.73M	141.12M
Operating Income	414.12M	72.42M
Net Income	355.76M	-177.29M
EPS	2.14	-0.63
Diluted EPS	2.10	-0.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.87	0.62
Operating Profit Margin	0.22	0.07
EBITDA Margin	0.29	0.10
Net Profit Margin	0.25	-0.06
Return on Equity	0.34	-0.07
Return on Assets	0.20
Return on Capital Employed	0.23	0.10

COM:ALKERMES

Alkermes

Last Close

27.70

22/11 21:00

Market Cap

3.89B

Beta: -

Volume Today

402

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	20.48	-284.91
P/B Ratio	3.24	2.68
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.17	4.30
EV Multiple	16.57	36.82

Metric
Days Sales Outstanding	78.13	161.17
Days Payables Outstanding	94.07	146.28
Days Inventory Outstanding	352.33	172.88
Operating Cycle	441.02	229.31
Cash Conversion Cycle	441.02	55.48
Asset Turnover	0.81	0.84

Metric
Operating Cash Flow	401.35M	-90.32M
Free Cash Flow	353.31M	-198.34M
Cash Flow to Debt	1.50	0.83
Operating Cash Flow/Sales	0.29	0.07
Free Cash Flow Yield	0.06	0.00

Metric
Cash & Equivalents	457.47M	195.92M
Accounts Receivable	-44.51M	114.46M
Inventory	186.41M	296.69M
Goodwill	83.03M	7.95M
Debt to Capitalization	0.22	0.14
Debt to Assets	0.13	0.26
Current Ratio	3.12	1.93
Quick Ratio	2.77	0.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06	0.00
R&D to Revenue	0.19
SG&A to Revenue	0.17